- ►cardiobarbanza.com [PDF] DM Nathan, JB Buse, MB Davidson, E … - Diabetologia, 2009 - Springer Page 1. CONSENSUS STATEMENT UPDATE Medical management of hyperglycaemia in type
2 diabetes mellitus: a consensus algorithm for the initiation ... Cited by 1039 - Related articles - BL Direct - All 92 versions
DM Kendall, MC Riddle, J Rosenstock, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg),
−0.6 ± 0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs.
placebo), yielding placebo-adjusted reductions of −1.0% (10 μg) and ... Cited by 542 - Related articles - All 11 versions
- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46
± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms,
respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA ... Cited by 453 - Related articles - BL Direct - All 13 versions
DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that
stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying,
and reduces appetite and food intake. Therapeutic approaches for enhancing ... Cited by 403 - Related articles - All 10 versions
- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal medicine, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control
(defined as hemoglobin A1c level ranging from 7.0% to 10.0%) despite combination
metformin and sulfonylurea therapy. Intervention: Exenatide, 10 g twice ... Cited by 329 - Related articles - BL Direct - All 7 versions
AJ Scheen, N Finer, P Hollander, MD Jensen, … - The Lancet, 2006 - Elsevier 1047 overweight or obese type 2 diabetes patients (body-mass index 27–40 kg/m
2 ) with a haemoglobin A 1c (HbA 1c ) concentration of 6·5–10·0% (mean 7·3%
[SD 0·9] at baseline) already on metformin or sulphonylurea monotherapy ... Cited by 282 - Related articles - All 12 versions
- ►wanfang.gov.tw [DOC] RE Amori, J Lau, AG Pittas - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 240 - Related articles - BL Direct - All 8 versions
S Bonner-Weir, GC Weir - Nature biotechnology, 2005 - nature.com Two major initiatives are under way to correct the -cell deficit of diabetes:
one would generate -cells ex vivo that are suitable for transplantation, and the
second would stimulate regeneration of -cells in the pancreas. Studies of ... Cited by 172 - Related articles - All 3 versions
L Blonde, EJ Klein, J Han, B Zhang, SM Mac, … - Diabetes, Obesity & Metabolism, 2006 - pt.wkhealth.com Results: Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age
56 ± 10 years, weight 99 ± 21 kg, body mass index 34 ± 6 kg/m 2 , A1C 8.3 ±
1.0% (mean ± SD)]. Reduction in A1C from baseline to week 30 [-0.9 ± 0.1% ... Cited by 172 - Related articles - BL Direct - All 6 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion,
biological actions, and therapeutic relevance of the incretin peptides
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ... Cited by 172 - Related articles - All 25 versions
